MicroRNAs in cancer - from research to therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1805, Issue 2, 2010, Pages 209-217

  Cho, William C S ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Cancer; Locked nucleic acid; MicroRNA; Target gene; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MICRORNA; MICRORNA 101; MICRORNA 106B; MICRORNA 106B 25; MICRORNA 10B; MICRORNA 122; MICRORNA 128; MICRORNA 16; MICRORNA 17; MICRORNA 17 92; MICRORNA 18A; MICRORNA 195; MICRORNA 20A; MICRORNA 21; MICRORNA 22; MICRORNA 222; MICRORNA 23A; MICRORNA 23B; MICRORNA 25; MICRORNA 26A; MICRORNA 27A; MICRORNA 31; MICRORNA 34C; MICRORNA 92; MICRORNA 93; MICRORNA 96; MICRORNA 98; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; RNA DEGRADATION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS;

EID: 77949261485     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.11.003     Document Type: Review

References (69)

1. Cho W.C. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6 (2007) 60
2. Cho W.C. Omics approaches in cancer research. In: Cho W.C. (Ed). An omics perspective on cancer research (2010), Springer, Berlin, New York 1-9
3. Cho W.C. Updates in cancer research: insights from the AACR 100th Annual Meeting. Expert Rev. Mol. Diagn. 9 (2009) 411-416
4. Galderisi U., Jori F.P., and Giordano A. Cell cycle regulation and neural differentiation. Oncogene 22 (2003) 5208-5219
5. Bandi N., Zbinden S., Gugger M., Arnold M., Kocher V., Hasan L., Kappeler A., Brunner T., and Vassella R. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69 (2009) 5553-5559
6. Liu X., Sempere L.F., Galimberti F., Freemantle S.J., Black C., Dragnev K.H., Ma Y., Fiering S., Memoli V., Li H., DiRenzo J., Korc M., Cole C.N., Bak M., Kauppinen S., and Dmitrovsky E. Uncovering growth-suppressive microRNAs in lung cancer. Clin. Cancer Res. 15 (2009) 1177-1183
7. 1/S transition of human hepatocellular carcinoma cells. Hepatology 50 (2009) 113-121
8. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., and Mendell J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137 (2009) 1005-1017
9. Fornari F., Gramantieri L., Giovannini C., Veronese A., Ferracin M., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Tavolari S., Chieco P., Negrini M., and Bolondi L. miR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 69 (2009) 5761-5767
10. Inomata M., Tagawa H., Guo Y.M., Kameoka Y., Takahashi N., and Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113 (2009) 396-402
11. Kan T., Sato F., Ito T., Matsumura N., David S., Cheng Y., Agarwal R., Paun B.C., Jin Z., Olaru A.V., Selaru F.M., Hamilton J.P., Yang J., Abraham J.M., Mori Y., and Meltzer S.J. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 136 (2009) 1689-1700
12. Kim Y.K., Yu J., Han T.S., Park S.Y., Namkoong B., Kim D.H., Hur K., Yoo M.W., Lee H.J., Yang H.K., and Kim V.N. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 37 (2009) 1672-1681
13. Hsu P.Y., Deatherage D.E., Rodriguez B.A., Liyanarachchi S., Weng Y.I., Zuo T., Liu J., Cheng A.S., and Huang T.H. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res. 69 (2009) 5936-5945
14. Kato M., Paranjape T., Ullrich R., Nallur S., Gillespie E., Keane K., Esquela-Kerscher A., Weidhaas J.B., and Slack F.J. The miR-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 28 (2009) 2419-2424
15. Zenz T., Mohr J., Eldering E., Kater A.P., Bühler A., Kienle D., Winkler D., Dürig J., van Oers M.H., Mertens D., Döhner H., and Stilgenbauer S. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113 (2009) 3801-3808
16. Wang X., Wang H.K., McCoy J.P., Banerjee N.S., Rader J.S., Broker T.R., Meyers C., Chow L.T., and Zheng Z.M. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15 (2009) 637-647
17. Sampath D., Calin G.A., Puduvalli V.K., Gopisetty G., Taccioli C., Liu C.G., Ewald B., Liu C., Keating M.J., and Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113 (2009) 3744-3753
18. Manni I., Artuso S., Careccia S., Rizzo M.G., Baserga R., Piaggio G., and Sacchi A. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J. 23 (2009) 3957-3966
19. Lee K.H., Chen Y.L., Yeh S.D., Hsiao M., Lin J.T., Goan Y.G., and Lu P.J. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28 (2009) 3360-3370
20. Bhat-Nakshatri P., Wang G., Collins N.R., Thomson M.J., Geistlinger T.R., Carroll J.S., Brown M., Hammond S., Srour E.F., Liu Y., and Nakshatri H. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 37 (2009) 4850-4861
21. Zhang Y., Chao T., Li R., Liu W., Chen Y., Yan X., Gong Y., Yin B., Liu W., Qiang B., Zhao J., Yuan J., and Peng X. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J. Mol. Med. 87 (2009) 43-51
22. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.L., De Marzo A.M., Van Eyk J.E., Mendell J.T., and Dang C.V. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458 (2009) 762-765
23. Uziel T., Karginov F.V., Xie S., Parker J.S., Wang Y.D., Gajjar A., He L., Ellison D., Gilbertson R.J., Hannon G., and Roussel M.F. The miR-17∼92 cluster collaborates with the sonic hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 2812-2817
24. Northcott P.A., Fernandez L.A., Hagan J.P., Ellison D.W., Grajkowska W., Gillespie Y., Grundy R., Van Meter T., Rutka J.T., Croce C.M., Kenney A.M., and Taylor M.D. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 69 (2009) 3249-3255
25. Zhang Z., Sun H., Dai H., Walsh R.M., Imakura M., Schelter J., Burchard J., Dai X., Chang A.N., Diaz R.L., Marszalek J.R., Bartz S.R., Carleton M., Cleary M.A., Linsley P.S., and Grandori C. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8 (2009) 2756-2768
26. Li Y., Vandenboom II T.G., Kong D., Wang Z., Ali S., Philip P.A., and Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69 (2009) 6704-6712
27. Kong D., Li Y., Wang Z., Banerjee S., Ahmad A., Kim H.R., and Sarkar F.H. The miR-200 regulates PDGF-D mediated epithelial-mesenchymal transition, adhesion and invasion of prostate cancer cells. Stem Cells 27 (2009) 1712-1721
28. Guttilla I.K., and White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 284 (2009) 23204-23216
29. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., Zakrzewski J., Blochin E., Rose A., Bogunovic D., Polsky D., Wei J., Lee P., Belitskaya-Levy I., Bhardwaj N., Osman I., and Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 1814-1819
30. Cho W.C., Chow A.S., and Au J.S. Restoration of tumor suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 45 (2009) 2197-2206
31. Seike M., Goto A., Okano T., Bowman E.D., Schetter A.J., Horikawa I., Mathe E.A., Jen J., Yang P., Sugimura H., Gemma A., Kudoh S., Croce C.M., and Harris C.C. miR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 12085-12090
32. Huang T.H., Wu F., Loeb G.B., Hsu R., Heidersbach A., Brincat A., Horiuchi D., Lebbink R.J., Mo Y.Y., Goga A., and McManus M.T. Upregulation of miR-21 by HER2/neu signaling promotes cell invasion. J. Biol. Chem. 284 (2009) 18515-18524
33. Epis M.R., Giles K.M., Barker A., Kendrick T.S., and Leedman P.J. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J. Biol. Chem. 284 (2009) 24696-24704
34. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., Ménard S., Croce C.M., and Tagliabue E. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69 (2009) 2195-2200
35. La Rocca G., Badin M., Shi B., Xu S.Q., Deangelis T., Sepp-Lorenzinoi L., and Baserga R. Mechanism of growth inhibition by microRNA 145: the role of the IGF-I receptor signaling pathway. J. Cell. Physiol. 220 (2009) 485-491
36. Lu L., Katsaros D., Shaverdashvili K., Qian B., Wu Y., de la Longrais I.A., Preti M., Menato G., and Yu H. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur. J. Cancer 45 (2009) 2212-2218
37. Dahlman-Wright K., Cavailles V., Fuqua S.A., Jordan V.C., Katzenellenbogen J.A., Korach K.S., Maggi A., Muramatsu M., Parker M.G., and Gustafsson J.A. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 58 (2006) 773-781
38. Pandey D.P., and Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha Mrna. Mol. Cell. Biol. 29 (2009) 3783-3790
39. Liu W.H., Yeh S.H., Lu C.C., Yu S.L., Chen H.Y., Lin C.Y., Chen D.S., and Chen P.J. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 136 (2009) 683-693
40. Göke R., Gregel C., Göke A., Arnold R., Schmidt H., and Lankat-Buttgereit B. Programmed cell death protein 4 (PDCD4) acts as a tumor suppressor in neuroendocrine tumor cells. Ann. N.Y. Acad. Sci. 1014 (2004) 220-221
41. Bourguignon L.Y., Spevak C.C., Wong G., Xia W., and Gilad E. Hyaluronan-CD44 interaction with PKC-epsilon promotes oncogenic signaling by the stem cell marker, Nanog and the production of microRNA-21 leading to downregulation of the tumor suppressor protein, PDCD4, anti-apoptosis and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 284 (2009) 26533-26546
42. Du J., Yang S., An D., Hu F., Yuan W., Zhai C., and Zhu T. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res. 19 (2009) 487-496
43. Wickramasinghe N.S., Manavalan T.T., Dougherty S.M., Riggs K.A., Li Y., and Klinge C.M. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37 (2009) 2584-2595
44. Yamamichi N., Shimomura R., Inada K., Sakurai K., Haraguchi T., Ozaki Y., Fujita S., Mizutani T., Furukawa C., Fujishiro M., Ichinose M., Shiogama K., Tsutsumi Y., Omata M., and Iba H. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin. Cancer Res. 15 (2009) 4009-4016
45. Hiyoshi Y., Kamohara H., Karashima R., Sato N., Imamura Y., Nagai Y., Yoshida N., Toyama E., Hayashi N., Watanabe M., and Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin. Cancer Res. 15 (2009) 1915-1922
46. Selaru F.M., Olaru A.V., Kan T., David S., Cheng Y., Mori Y., Yang J., Paun B., Jin Z., Agarwal R., Hamilton J.P., Abraham J., Georgiades C., Alvarez H., Vivekanandan P., Yu W., Maitra A., Torbenson M., Thuluvath P.J., Gores G.J., LaRusso N.F., Hruban R., and Meltzer S.J. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49 (2009) 1595-1601
47. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., and Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 8 (2009) 1067-1074
48. Tsang W.P., and Kwok T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 21 (2009) 140-146
49. Chen L., Yan H.X., Yang W., Hu L., Yu L.X., Liu Q., Li L., Huang D.D., Ding J., Shen F., Zhou W.P., Wu M.C., and Wang H.Y. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J. Hepatol. 50 (2009) 358-369
50. Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., and Zhuang S.M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69 (2009) 1135-1142
51. Saito Y., Suzuki H., Tsugawa H., Nakagawa I., Matsuzaki J., Kanai Y., and Hibi T. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28 (2009) 2738-2744
52. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta 1756 (2005) 81-82
53. Torrisani J., Bournet B., du Rieu M.C., Bouisson M., Souque A., Escourrou J., Buscail L., and Cordelier P. let-7 microRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum. Gene Ther. 20 (2009) 831-844
54. Tsang W.P., and Kwok T.T. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30 (2009) 953-959
55. Chen X., Guo X., Zhang H., Xiang Y., Chen J., Yin Y., Cai X., Wang K., Wang G., Ba Y., Zhu L., Wang J., Yang R., Zhang Y., Ren Z., Zen K., Zhang J., and Zhang C.Y. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28 (2009) 1385-1392
56. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szász A.M., Wang Z.C., Brock J.E., Richardson A.L., and Weinberg R.A. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137 (2009) 1032-1046
57. Sasayama T., Nishihara M., Kondoh T., Hosoda K., and Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int. J. Cancer 125 (2009) 1407-1413
58. Gondi C.S., and Rao J.S. Concepts in in vivo siRNA delivery for cancer therapy. J. Cell. Physiol. 220 (2009) 285-291
59. Elmén J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Ørum H., Koch T., and Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33 (2005) 439-447
60. Frieden M., and Ørum H. Locked nucleic acid holds promise in the treatment of cancer. Curr. Pharm. Des. 14 (2008) 1138-1142
61. Fluiter K., Frieden M., Vreijling J., Rosenbohm C., De Wissel M.B., Christensen S.M., Koch T., Ørum H., and Baas F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem 6 (2005) 1104-1109
62. Hansen J.B., Fisker N., Westergaard M., Kjaerulff L.S., Hansen H.F., Thrue C.A., Rosenbohm C., Wissenbach M., Ørum H., and Koch T. SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther. 7 (2008) 2736-2745
63. Roberts J., Palma E., Sazani P., Ørum H., Cho M., and Kole R. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther. 14 (2006) 471-475
64. Frieden M., and Ørum H. The application of locked nucleic acids in the treatment of cancer. IDrugs 9 (2006) 706-711
65. Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjärn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., and Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 452 (2008) 896-899
66. Worm J., Stenvang J., Petri A., Frederiksen K.S., Obad S., Elmén J., Hedtjärn M., Straarup E.M., Hansen J.B., and Kauppinen S. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res. 37 (2009) 5784-5792
67. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., and Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 40 (2008) 43-50
68. Cho W.C. Role of miRNAs in lung cancer. Expert Rev. Mol. Diagn. 9 (2009) 773-776
69. W.C. Cho, MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy, Int. J. Biochem. Cell. Biol. (2010), doi:10.1016/j.biocel.2009.12.014.